Business · Singapore Bureau
Novartis shares tumble on heart-drug trial setback
Swiss pharmaceutical giant Novartis saw its stock decline nearly 4% following disappointing results from a late-stage heart medication trial. The setback compounds earlier challenges for the company, including a halt to experimental cell therapy trials.
LSN Singapore ·
Novartis shares fell sharply in trading after the company disclosed negative outcomes from an advanced-stage trial of a cardiovascular treatment. The decline reflects growing concerns about the drugmaker's pipeline as it grapples with multiple developmental obstacles across its research portfolio.
The heart-drug trial failure marks a significant blow to Novartis's near-term growth prospects, particularly as the pharmaceutical sector faces intense pressure to deliver viable new therapies. The company had previously announced a pause in trials for an experimental cell therapy programme, signalling a period of consolidation for the Swiss firm's research initiatives.
The stock decline extended beyond Novartis to competitors in the sector. Rival biotechnology firm Amgen also experienced share price pressure, suggesting investor concerns may be rippling across the industry more broadly. Such contagion effects are common when major players in the pharmaceutical space encounter major setbacks, as they often signal broader challenges in drug development timelines and regulatory pathways.
The failures underscore the inherent risks in pharmaceutical research and development, where late-stage trial disappointments can erase years of investment and reshape corporate strategy. Novartis will likely need to reassess its therapeutic priorities and potential restructuring of its research spend in response to these setbacks.